News

Device that assesses brain activity may help diagnose Parkinson’s

Delphi-MD, a system that measures brain activity, may be used for the early diagnosis of Parkinson’s disease and for differentiating between its subtypes, particularly those marked by rapid disease progression, a study shows. The technology, developed by Quantalx Neuroscience, provides direct, real-time imaging of the brain’s electrical…

SandboxAQ joins MJFF initiative to target Parkinson’s LRRK2 gene

SandboxAQ has signed a $25 million research grant through an initiative of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop new treatments that target the LRRK2 gene, mutations in which are one of the most common genetic causes of Parkinson’s disease. Under the partnership, which…

Speech changes before, after diagnosis evident in celebrities

Analyzing vocal recordings could help in detecting Parkinson’s disease at early stages, according to a study that tested the idea using decades’ worth of recordings from celebrities who went on to develop the neurodegenerative condition. “This study shows that early patterns of [speech changes] are detectable up to 10…

Motor imagery impaired in Parkinson’s patients, study finds

Besides motor challenges, people with Parkinson’s disease have difficulty with motor imagery, or generating a mental representation of a movement, a study showed. That’s particularly true for the more affected side of the body. “Even when people with Parkinson’s think about movement, it’s different for their more affected side,”…

Metabolic syndrome linked to dementia risk in Parkinson’s study

Metabolic syndrome, a cluster of conditions that can increase the risk of heart disease, diabetes, and stroke, is associated with a higher risk of developing dementia in people with Parkinson’s disease, according to recent research. “These findings advocate for comprehensive management of MetS [metabolic syndrome] as a pivotal strategy…

$50M raised to advance potentially better brain stimulation device

Inbrain Neuroelectronics has raised $50 million in funding to continue developing its brain-computer interface (BCI) technology using ultra-thin graphene electrodes, designed for more personalized treatment of people with Parkinson’s disease and other conditions. BCIs are implanted devices that can be used to decode and modulate brain activity.